Title

Study of Meloxicam Capsules to Treat Osteoarthritis Pain
A Phase 3, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Fixed-Dose, Parallel-Group, Efficacy, and Safety Study of Meloxicam SoluMatrix™ Capsules in Patients With Pain Due to Osteoarthritis of the Knee or Hip
  • Phase

    Phase 3
  • Study Type

    Interventional
  • Intervention/Treatment

    meloxicam ...
  • Study Participants

    403
The purpose of this study is to determine whether Meloxicam [Test] Capsules are safe and effective for the treatment of osteoarthritis pain of the knee or hip.
Study Started
Feb 28
2013
Primary Completion
Oct 31
2013
Study Completion
Oct 31
2013
Results Posted
Mar 11
2015
Estimate
Last Update
Mar 11
2015
Estimate

Drug Meloxicam Test Capsules

Drug Meloxicam Test Capsules

Drug Placebo Capsules

Meloxicam Test Capsules low dose QD Experimental

Meloxicam Test Capsules low dose QD

Meloxicam Test Capsules high dose QD Experimental

Meloxicam Test Capsules high dose QD

Placebo Capsule QD Placebo Comparator

Placebo Capsule QD

Criteria

Inclusion Criteria:

Primary diagnosis of Functional Class I-III OA of the hip or knee
Chronic user of nonsteroidal anti-inflammatory drugs (NDAIDs) and/or acetaminophen for OA pain
Discontinued all analgesic therapy at Screening
For women of child-bearing potential: a woman who is not pregnant and not nursing, and who is practicing an acceptable method of birth control

Exclusion Criteria:

History of allergic reaction or clinically significant intolerance to acetaminophen, aspirin, or any NSAIDs, including meloxicam
Requires continuous use of opioid or opioid combination products to control OA pain of the knee or hip
Clinically significant unstable cardiac, respiratory, neurological, immunological, hematological, or renal disease
Significant difficulties swallowing capsules or unable to tolerate oral medication
Previous participation in another clinical study of Meloxicam Capsules or received any investigational drug or device or investigational therapy within 30 days before Screening

Summary

Meloxicam 5 mg Once Daily

Meloxicam 10 mg Once Daily

Placebo

All Events

Event Type Organ System Event Term Meloxicam 5 mg Once Daily Meloxicam 10 mg Once Daily Placebo

Change From Baseline to Week 12 After Trial Entry in Osteoarthritis Pain Measured on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score.

The pain in subjects with osteoarthritis was measured using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale score. The WOMAC pain subscale score is calculated as the average of the visual analogue scale (VAS) scores from 5 pain subscale questions. Subjects mark the VAS, which is a horizontal line 100 mm in length, with a single vertical line to indicate their pain level over the last 24 hours, with 0 mm representing "No Pain" and 100 mm representing "Extreme Pain". The WOMAC pain subscale score difference is calculated as the WOMAC pain subscale score assessed at Week 12 minus the WOMAC pain subscale score assessed at baseline.

Meloxicam 5 mg Once Daily

-36.52
mm (Least Squares Mean)
Standard Error: 2.485

Meloxicam 10 mg Once Daily

-34.41
mm (Least Squares Mean)
Standard Error: 2.678

Placebo

-25.68
mm (Least Squares Mean)
Standard Error: 2.636

Change From Baseline to Week 2 After Trial Entry in Osteoarthritis Pain Measured on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score.

The pain in subjects with osteoarthritis was measured using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale score. The WOMAC pain subscale score is calculated as the average of the visual analogue scale (VAS) scores from 5 pain subscale questions. Subjects mark the VAS, which is a horizontal line 100 mm in length, with a single vertical line to indicate their pain level over the last 24 hours, with 0 mm representing "No Pain" and 100 mm representing "Extreme Pain". The WOMAC pain subscale score difference was calculated as the WOMAC pain subscale score assessed at Week 2 minus the WOMAC pain subscale score assessed at baseline.

Meloxicam 5 mg Once Daily

-26.12
mm (Least Squares Mean)
Standard Error: 2.217

Meloxicam 10 mg Once Daily

-20.42
mm (Least Squares Mean)
Standard Error: 2.397

Placebo

-16.51
mm (Least Squares Mean)
Standard Error: 2.367

Change From Baseline to Week 6 After Trial Entry in Osteoarthritis Pain Measured on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score.

The pain in subjects with osteoarthritis was measured using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale score. The WOMAC pain subscale score is calculated as the average of the visual analogue scale (VAS) scores from 5 pain subscale questions. Subjects mark the VAS, which is a horizontal line 100 mm in length, with a single vertical line to indicate their pain level over the last 24 hours, with 0 mm representing "No Pain" and 100 mm representing "Extreme Pain". The WOMAC pain subscale score difference was calculated as the WOMAC pain subscale score assessed at Week 6 minus the WOMAC pain subscale score assessed at baseline.

Meloxicam 5 mg Once Daily

-31.31
mm (Least Squares Mean)
Standard Error: 2.339

Meloxicam 10 mg Once Daily

-30.82
mm (Least Squares Mean)
Standard Error: 2.531

Placebo

-20.98
mm (Least Squares Mean)
Standard Error: 2.503

Change From Baseline to the Average of Weeks 2, 6, and 12 After Trial Entry in Osteoarthritis Pain Measured on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score.

The pain in subjects with osteoarthritis was measured using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale score. The WOMAC pain subscale score is calculated as the average of the visual analogue scale (VAS) scores from 5 pain subscale questions. Subjects mark the VAS, which is a horizontal line 100 mm in length, with a single vertical line to indicate their pain level over the last 24 hours, with 0 mm representing "No Pain" and 100 mm representing "Extreme Pain". The WOMAC pain subscale score difference was calculated as the WOMAC pain subscale score assessed at Weeks 2, 6, and 12 minus the WOMAC pain subscale score assessed at baseline.

Meloxicam 5 mg Once Daily

-30.51
mm (Least Squares Mean)
Standard Error: 2.151

Meloxicam 10 mg Once Daily

-27.89
mm (Least Squares Mean)
Standard Error: 2.337

Placebo

-20.07
mm (Least Squares Mean)
Standard Error: 2.318

Change From Baseline to Week 2 After Trial Entry in Osteoarthritis Pain, Stiffness, and Function Measured Using the Total Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Score.

Pain, stiffness, and function in subjects with osteoarthritis were measured using the Western Ontario and McMaster Universities (WOMAC) Index, which is a 24-item questionnaire. The total WOMAC score is calculated as the average of the mean visual analogue scale (VAS) scores from the questions in the pain, stiffness, and function subscales. Subjects mark the VAS, which is a horizontal line 100 mm in length, with a single vertical line to indicate their response to each of the questions, with 0 mm representing "No Pain, Stiffness, or Difficulty" and 100 mm representing "Extreme Pain, Stiffness, and Difficulty". The total WOMAC score difference was calculated as the total WOMAC score assessed at Week 2 minus the total WOMAC score assessed at baseline.

Meloxicam 5 mg Once Daily

-21.62
mm (Least Squares Mean)
Standard Error: 2.214

Meloxicam 10 mg Once Daily

-15.67
mm (Least Squares Mean)
Standard Error: 2.384

Placebo

-11.28
mm (Least Squares Mean)
Standard Error: 2.365

Change From Baseline to Week 6 After Trial Entry in Osteoarthritis Pain, Stiffness, and Function Measured Using the Total Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Score.

Pain, stiffness, and function in subjects with osteoarthritis were measured using the Western Ontario and McMaster Universities (WOMAC) Index, which is a 24-item questionnaire. The total WOMAC score is calculated as the average of the mean visual analogue scale (VAS) scores from the questions in the pain, stiffness, and function subscales. Subjects mark the VAS, which is a horizontal line 100 mm in length, with a single vertical line to indicate their response to each of the questions, with 0 mm representing "No Pain, Stiffness, or Difficulty" and 100 mm representing "Extreme Pain, Stiffness, and Difficulty". The total WOMAC score difference was calculated as the total WOMAC score assessed at Week 6 minus the total WOMAC score assessed at baseline.

Meloxicam 5 mg Once Daily

-25.86
mm (Least Squares Mean)
Standard Error: 2.367

Meloxicam 10 mg Once Daily

-25.45
mm (Least Squares Mean)
Standard Error: 2.554

Placebo

-16.03
mm (Least Squares Mean)
Standard Error: 2.537

Change From Baseline to Week 12 After Trial Entry in Osteoarthritis Pain, Stiffness, and Function Measured Using the Total Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Score.

Pain, stiffness, and function in subjects with osteoarthritis were measured using the Western Ontario and McMaster Universities (WOMAC) Index, which is a 24-item questionnaire. The total WOMAC score is calculated as the average of the mean visual analogue scale (VAS) scores from the questions in the pain, stiffness, and function subscales. Subjects mark the VAS, which is a horizontal line 100 mm in length, with a single vertical line to indicate their response to each of the questions, with 0 mm representing "No Pain, Stiffness, or Difficulty" and 100 mm representing "Extreme Pain, Stiffness, and Difficulty". The total WOMAC score difference was calculated as the total WOMAC score assessed at Week 12/early termination minus the total WOMAC score assessed at baseline.

Meloxicam 5 mg Once Daily

-29.85
mm (Least Squares Mean)
Standard Error: 2.518

Meloxicam 10 mg Once Daily

-29.71
mm (Least Squares Mean)
Standard Error: 2.706

Placebo

-19.72
mm (Least Squares Mean)
Standard Error: 2.678

Change From Baseline to the Average of Weeks 2, 6, and 12 After Trial Entry in Osteoarthritis Pain, Stiffness, and Function Measured Using the Total Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Score.

Pain, stiffness, and function in subjects with osteoarthritis were measured using the Western Ontario and McMaster Universities (WOMAC) Index, which is a 24-item questionnaire. The total (composite) WOMAC score is calculated as the average of the mean visual analogue scale (VAS) scores from the questions in the pain, stiffness, and function subscales. Subjects mark the VAS, which is a horizontal line 100 mm in length, with a single vertical line to indicate their response to each of the questions, with 0 mm representing "No Pain, Stiffness, or Difficulty" and 100 mm representing "Extreme Pain, Stiffness, and Difficulty". The total WOMAC score difference was calculated as the total WOMAC score assessed at Weeks 2, 6, and 12 minus the total WOMAC score assessed at baseline.

Meloxicam 5 mg Once Daily

-25.15
mm (Least Squares Mean)
Standard Error: 2.205

Meloxicam 10 mg Once Daily

-22.83
mm (Least Squares Mean)
Standard Error: 2.389

Placebo

-14.67
mm (Least Squares Mean)
Standard Error: 2.379

Change From Baseline to Week 2 After Trial Entry in Osteoarthritis Function Measured on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Function Subscale Score.

The function in osteoarthritis subjects within the past 24 hours was measured at baseline using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) function subscale score. The WOMAC function subscale score is calculated as the mean of the visual analogue scale scores from 17 function subscale questions. Subjects mark the VAS, which is a horizontal line 100 mm in length, with a single vertical line to indicate their functional limitation level over the last 24 hours, with 0 mm meaning "No Functional Limitation" and 100 mm meaning "Extreme Functional Limitation". The WOMAC function subscale score difference was calculated as the WOMAC function subscale score assessed at Week 2 minus the WOMAC function subscale score assessed at baseline.

Meloxicam 5 mg Once Daily

-20.45
mm (Least Squares Mean)
Standard Error: 2.270

Meloxicam 10 mg Once Daily

-14.41
mm (Least Squares Mean)
Standard Error: 2.445

Placebo

-10.0
mm (Least Squares Mean)
Standard Error: 2.423

Change From Baseline to Week 6 After Trial Entry in Osteoarthritis Function Measured on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Function Subscale Score.

The function in osteoarthritis subjects within the past 24 hours was measured at baseline using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) function subscale score. The WOMAC function subscale score is calculated as the mean of the visual analogue scale scores from 17 function subscale questions. Subjects mark the VAS, which is a horizontal line 100 mm in length, with a single vertical line to indicate their functional limitation level over the last 24 hours, with 0 mm meaning "No Functional Limitation" and 100 mm meaning "Extreme Functional Limitation". The WOMAC function subscale score difference was calculated as the WOMAC function subscale score assessed at Week 6 minus the WOMAC function subscale score assessed at baseline.

Meloxicam 5 mg Once Daily

-24.41
mm (Least Squares Mean)
Standard Error: 2.419

Meloxicam 10 mg Once Daily

-24.38
mm (Least Squares Mean)
Standard Error: 2.608

Placebo

-14.73
mm (Least Squares Mean)
Standard Error: 2.590

Change From Baseline to Week 12 After Trial Entry in Osteoarthritis Function Measured on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Function Subscale Score.

The function in osteoarthritis subjects within the past 24 hours was measured at baseline using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) function subscale score. The WOMAC function subscale score is calculated as the mean of the visual analogue scale scores from 17 function subscale questions. Subjects mark the VAS, which is a horizontal line 100 mm in length, with a single vertical line to indicate their functional limitation level over the last 24 hours, with 0 mm meaning "No Functional Limitation" and 100 mm meaning "Extreme Functional Limitation". The WOMAC function subscale score difference was calculated as the WOMAC function subscale score assessed at Week 12/early termination minus the WOMAC function subscale score assessed at baseline.

Meloxicam 5 mg Once Daily

-28.21
mm (Least Squares Mean)
Standard Error: 2.566

Meloxicam 10 mg Once Daily

-28.4
mm (Least Squares Mean)
Standard Error: 2.752

Placebo

-17.95
mm (Least Squares Mean)
Standard Error: 2.724

Change From Baseline to the Average of Weeks 2, 6, and 12 After Trial Entry in Osteoarthritis Function Measured on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Function Subscale Score.

The function in osteoarthritis subjects within the past 24 hours was measured at baseline using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) function subscale score. The WOMAC function subscale score is calculated as the mean of the visual analogue scale scores from 17 function subscale questions. Subjects mark the VAS, which is a horizontal line 100 mm in length, with a single vertical line to indicate their functional limitation level over the last 24 hours, with 0 mm meaning "No Functional Limitation" and 100 mm meaning "Extreme Functional Limitation". The WOMAC function subscale score difference was calculated as the WOMAC function subscale score assessed at Weeks 2, 6, and 12 minus the WOMAC function subscale score assessed at baseline.

Meloxicam 5 mg Once Daily

-23.78
mm (Least Squares Mean)
Standard Error: 2.254

Meloxicam 10 mg Once Daily

-21.7
mm (Least Squares Mean)
Standard Error: 2.441

Placebo

-13.26
mm (Least Squares Mean)
Standard Error: 2.429

Change From Baseline to Week 2 After Trial Entry in Osteoarthritis Stiffness Measured on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale Score.

The stiffness in osteoarthritis subjects within the past 24 hours was measured at baseline using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) stiffness subscale score. The WOMAC stiffness subscale score is calculated as the mean of the visual analogue scale scores from 2 stiffness subscale questions. Subjects mark the VAS, which is a horizontal line 100 mm in length, with a single vertical line to indicate their stiffness level over the last 24 hours, with 0 mm meaning "No Stiffness" and 100 mm meaning "Extreme Stiffness". The WOMAC stiffness subscale score difference was calculated as the WOMAC stiffness subscale score assessed at Week 2 minus the WOMAC stiffness subscale score assessed at baseline.

Meloxicam 5 mg Once Daily

-19.84
mm (Least Squares Mean)
Standard Error: 2.381

Meloxicam 10 mg Once Daily

-14.88
mm (Least Squares Mean)
Standard Error: 2.578

Placebo

-8.86
mm (Least Squares Mean)
Standard Error: 2.545

Change From Baseline to Week 6 After Trial Entry in Osteoarthritis Stiffness Measured on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale Score.

The stiffness in osteoarthritis subjects within the past 24 hours was measured at baseline using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) stiffness subscale score. The WOMAC stiffness subscale score is calculated as the mean of the visual analogue scale scores from 2 stiffness subscale questions. Subjects mark the VAS, which is a horizontal line 100 mm in length, with a single vertical line to indicate their stiffness level over the last 24 hours, with 0 mm meaning "No Stiffness" and 100 mm meaning "Extreme Stiffness". The WOMAC stiffness subscale score difference was calculated as the WOMAC stiffness subscale score assessed at Week 6 minus the WOMAC stiffness subscale score assessed at baseline.

Meloxicam 5 mg Once Daily

-26.52
mm (Least Squares Mean)
Standard Error: 2.559

Meloxicam 10 mg Once Daily

-23.39
mm (Least Squares Mean)
Standard Error: 2.767

Placebo

-14.3
mm (Least Squares Mean)
Standard Error: 2.737

Change From Baseline to Week 12 After Trial Entry in Osteoarthritis Stiffness Measured on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale Score.

The stiffness in osteoarthritis subjects within the past 24 hours was measured at baseline using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) stiffness subscale score. The WOMAC stiffness subscale score is calculated as the mean of the visual analogue scale scores from 2 stiffness subscale questions. Subjects mark the VAS, which is a horizontal line 100 mm in length, with a single vertical line to indicate their stiffness level over the last 24 hours, with 0 mm meaning "No Stiffness" and 100 mm meaning "Extreme Stiffness". The WOMAC stiffness subscale score difference was calculated as the WOMAC stiffness subscale score assessed at Week 12/early termination minus the WOMAC stiffness subscale score assessed at baseline.

Meloxicam 5 mg Once Daily

-29.68
mm (Least Squares Mean)
Standard Error: 2.691

Meloxicam 10 mg Once Daily

-28.1
mm (Least Squares Mean)
Standard Error: 2.902

Placebo

-18.74
mm (Least Squares Mean)
Standard Error: 2.857

Change From Baseline to the Average of Weeks 2, 6, and 12 After Trial Entry in Osteoarthritis Stiffness Measured on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale Score.

The stiffness in osteoarthritis subjects within the past 24 hours was measured at baseline using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) stiffness subscale score. The WOMAC stiffness subscale score is calculated as the mean of the visual analogue scale scores from 2 stiffness subscale questions. Subjects mark the VAS, which is a horizontal line 100 mm in length, with a single vertical line to indicate their stiffness level over the last 24 hours, with 0 mm meaning "No Stiffness" and 100 mm meaning "Extreme Stiffness". The WOMAC stiffness subscale score difference was calculated as the WOMAC stiffness subscale score assessed at Weeks 2, 6, and 12 minus the WOMAC stiffness subscale score assessed at baseline.

Meloxicam 5 mg Once Daily

-24.76
mm (Least Squares Mean)
Standard Error: 2.345

Meloxicam 10 mg Once Daily

-21.33
mm (Least Squares Mean)
Standard Error: 2.548

Placebo

-13.09
mm (Least Squares Mean)
Standard Error: 2.526

Total

402
Participants

Age, Continuous

60.7
years (Mean)
Standard Deviation: 9.01

Baseline Total Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Score

68.91
mm (Mean)
Standard Deviation: 15.870

Baseline Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Function Subscore

67.69
mm (Mean)
Standard Deviation: 17.505

Baseline Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score

72.64
mm (Mean)
Standard Deviation: 14.922

Baseline Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscore

70.71
mm (Mean)
Standard Deviation: 18.363

Body Mass Index

30.9
kg/m^2 (Mean)
Standard Deviation: 5.01

Height

168.5
cm (Mean)
Standard Deviation: 10.10

Weight

88.1
kg (Mean)
Standard Deviation: 17.06

Ethnicity (NIH/OMB)

Race/Ethnicity, Customized

Sex: Female, Male

Overall Study

Meloxicam 5 mg Once Daily

Meloxicam 10 mg Once Daily

Placebo

Drop/Withdrawal Reasons

Meloxicam 5 mg Once Daily

Meloxicam 10 mg Once Daily

Placebo